Epizyme Inc. has its first product approval with the 23 January clearance by the US Food and Drug Administration of Tazverik (tazemetostat) for non-surgical, metastatic or locally advanced epithelioid sarcoma, but that indication largely is meant to clear the way for the first-in-class EZH2 inhibitor to obtain approval for follicular lymphoma and other larger oncology indications.
“We've always viewed this as a way to get into the market and build over time and be prepared for...






